Daily Fluctuations in Brain-Derived Neurotrophic Factor and Cognition: Effects of Vigorous Exercise

February 4, 2026 updated by: University of Padova

Daily Fluctuations in Brain-Derived Neurotrophic Factor and Cognitive Performance: Effects of Acute Physical Exercise

Cognitive functions are fundamental to everyday life, underpinning the mental processes required to perform any activity. Recent studies have shown that improved cognitive performance is associated with elevated levels of brain-derived neurotrophic factor (BDNF), which can be increased through an acute bout of physical activity. However, daily variations of BDNF serum and plasma remain poorly characterised and are not fully understood, and their correlation with daily variations in cognitive performance has not been previously explored. This study examines:

1) the correlation between daily BDNF fluctuations and cognitive performance. 2) whether a single session of exercise can elevate BDNF levels and lead to measurable cognitive improvements.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

15

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • PD
      • Padua, PD, Italy, 10034
        • Department of Biomedical Sciences, University of Padua

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • an age between 18-40 years old
  • no history of mental or physical diseases (of a neurological, psychogenic, musculoskeletal, cardiorespiratory or systemic nature)
  • MoCA score higher than 26

Exclusion Criteria:

  • smokers
  • individuals experiencing sleep-wake cycle disturbances in the week prior to the study
  • consumers of medications with CNS effects

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: BDNF arm
Every subject will be tested on day 1 and day 2 with the same protocol. Blood samples will be collected at five time points throughout the workday: 09:00 (T1), 11:00 (T2), 13:00 (T3), 15:00 (T4), and 17:00 (T5), to assess potential diurnal variations in BDNF. Cognitive performance will be evaluated using the Psychomotor Vigilance Test (PVT), the Flanker task, and the Digit Span Backwards test at T1, T3, and T5. On the second intervention day, the same protocol will be followed, with the addition of a 15-minute single bout of high-intensity physical activity executed at T4.
A five-minute bout of exercise at high intensity (75% of HRmax) repeated for two rounds with a minute rest between rounds. The bout consists of 5 exercises: BW squat, jumping jacks, lunges, crunches and step up. The modality is, in one minute for every exercise, 30 seconds of work and 30 seconds of rest

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Levels of Serum BDNF (ng/ml)
Time Frame: blood samples were collected on day one and day two at five specific time points: 9 a.m. (t1), 11 a.m. (t2), 1 p.m. (t3), 3 p.m. (t4), 5 p.m. (t5)
Blood samples for serum BDNF concentration analysis were collected using a Clot Activator Tube (CAT) and gently swirled ten times, upside down. They were then incubated at room temperature for 30 minutes to allow clot formation. Subsequently, the samples were centrifuged at 1100 g and 4 °C for 10 minutes, and then, the serum was collected, aliquoted, and stored at -80 °C. The analysis of BDNF was performed using an enzyme-linked immunosorbent assay (ELISA) kit, following the manufacturer's instructions (ab212166 - Human BDNF SimpleStep ELISA Kit).
blood samples were collected on day one and day two at five specific time points: 9 a.m. (t1), 11 a.m. (t2), 1 p.m. (t3), 3 p.m. (t4), 5 p.m. (t5)
inhibitory control
Time Frame: The test was performed for each participant on day one and two at three predefined time points 9 a.m. (t1), 1 p.m. (t3), 5 p.m. (t5)
Inhibitory control was assessed with the Flanker Task. During the task, participants are required to indicate the left-right orientation of a centrally presented stimulus while inhibiting attention to the potentially incongruent stimuli surrounding it (e.g., flankers on either side). The principal outcomes for this task are total errors, the mean reaction time for incongruent and congruent stimuli, and the conflict cost (the difference between the mean reaction times for incongruent and congruent stimuli)
The test was performed for each participant on day one and two at three predefined time points 9 a.m. (t1), 1 p.m. (t3), 5 p.m. (t5)
sustained attention and vigilance
Time Frame: The test was performed for each participant on day one and two at three predefined time points 9 a.m. (t1), 1 p.m. (t3), 5 p.m. (t5)
Sustained attention and vigilance were assessed with the Psychomotor Vigilance Task. Participants are presented with a visual stimulus (a simple light) that appears at random inter-stimulus intervals (between 2 and 10 seconds). When the stimulus appears, the participants are required to respond as quickly as possible. The primary outcome for this test is the mean reaction time
The test was performed for each participant on day one and two at three predefined time points 9 a.m. (t1), 1 p.m. (t3), 5 p.m. (t5)
working memory (short-term memory)
Time Frame: The test was performed for each participant on day one and two at three predefined time points 9 a.m. (t1), 1 p.m. (t3), 5 p.m. (t5)
Working memory was assessed with the Digit Span Backwards, in which participants are presented with a series of digits and then asked to recall them in reverse order. The main outcome for this test is the memory span.
The test was performed for each participant on day one and two at three predefined time points 9 a.m. (t1), 1 p.m. (t3), 5 p.m. (t5)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Antonio Paoli, University of Padua Department of Biomedical Sciences

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 1, 2025

Primary Completion (Actual)

December 23, 2025

Study Completion (Actual)

December 23, 2025

Study Registration Dates

First Submitted

January 7, 2026

First Submitted That Met QC Criteria

January 26, 2026

First Posted (Actual)

February 3, 2026

Study Record Updates

Last Update Posted (Actual)

February 9, 2026

Last Update Submitted That Met QC Criteria

February 4, 2026

Last Verified

October 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on BDNF

Clinical Trials on Exercise

Subscribe